Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1805 2
1806 2
1883 1
1928 1
1941 1
1948 1
1949 1
1985 1
1992 6
1993 1
1994 3
1995 5
1996 8
1997 14
1998 12
1999 13
2000 22
2001 16
2002 21
2003 13
2004 10
2005 19
2006 16
2007 22
2008 19
2009 21
2010 16
2011 18
2012 16
2013 14
2014 27
2015 47
2016 64
2017 75
2018 65
2019 81
2020 87
2021 98
2022 77
2023 73
2024 40

Text availability

Article attribute

Article type

Publication date

Search Results

956 results

Results by year

Filters applied: . Clear all
Page 1
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
de Latour RP, Szer J, Weitz IC, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro CM, Nishimori H, Ajayi T, Al-Adhami M, Deschatelets P, Francois C, Grossi F, Risitano AM, Hillmen P. de Latour RP, et al. Lancet Haematol. 2022 Sep;9(9):e648-e659. doi: 10.1016/S2352-3026(22)00210-1. Lancet Haematol. 2022. PMID: 36055332 Clinical Trial.
BACKGROUND: In the PEGASUS trial, the complement C3 inhibitor, pegcetacoplan, showed superiority to eculizumab in improving haematological outcomes in adult patients with paroxysmal nocturnal haemoglobinuria and suboptimal response to eculizumab at 16 weeks. The aim of the …
BACKGROUND: In the PEGASUS trial, the complement C3 inhibitor, pegcetacoplan, showed superiority to eculizumab in improving haematolo …
Pegasus causes inherited thrombocytopenia.
Vannucchi AM. Vannucchi AM. Blood. 2019 Dec 5;134(23):2000-2002. doi: 10.1182/blood.2019002181. Blood. 2019. PMID: 31805194 Free article. No abstract available.
[PEGASUS or COMPASS? A guide for a wise clinical choice.].
Brunetti ND, De Gennaro L, Di Biase M, Caldarola P. Brunetti ND, et al. Recenti Prog Med. 2019 Nov;110(11):518-520. doi: 10.1701/3265.32325. Recenti Prog Med. 2019. PMID: 31808430 Italian.
The recent publication of the PEGASUS and COMPASS studies could have a great influence on the clinical management of patients with stable ischemic heart disease. ...
The recent publication of the PEGASUS and COMPASS studies could have a great influence on the clinical management of patients with st …
Pegasus, a small extracellular peptide enhancing short-range diffusion of Wingless.
Magny EG, Platero AI, Bishop SA, Pueyo JI, Aguilar-Hidalgo D, Couso JP. Magny EG, et al. Nat Commun. 2021 Sep 27;12(1):5660. doi: 10.1038/s41467-021-25785-z. Nat Commun. 2021. PMID: 34580289 Free PMC article.
Pegasus is secreted, and co-localizes and co-immunoprecipitates with Wingless, suggesting their physical interaction. Finally, measurements of fixed and in-vivo Wingless gradients support that Pegasus increases Wingless diffusion in order to enhance its signalling. …
Pegasus is secreted, and co-localizes and co-immunoprecipitates with Wingless, suggesting their physical interaction. Finally, measur …
Editorial on PEGASUS - TIMI 54.
Trantalis G, Katsi V, Toutouzas K, Tousoulis D. Trantalis G, et al. Int J Cardiol. 2016 Jul 15;215:34-6. doi: 10.1016/j.ijcard.2016.03.209. Epub 2016 Apr 6. Int J Cardiol. 2016. PMID: 27107542 No abstract available.
Editorial on PEGASUS-TIMI 54.
Magnani G, Bonaca MP, Sabatine MS. Magnani G, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Oct;1(4):217-9. doi: 10.1093/ehjcvp/pvv030. Epub 2015 Jun 23. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27532444 No abstract available.
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.
Wong RSM. Wong RSM. Ther Adv Hematol. 2022 Jul 28;13:20406207221114673. doi: 10.1177/20406207221114673. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35923770 Free PMC article. Review.
This review summarizes findings from three studies in complement-inhibitor-naive patients with PNH (PADDOCK [phase Ib], PALOMINO [phase IIa], PRINCE [phase III; pegcetacoplan versus standard treatment excluding complement-inhibitors]), and one phase III study (PEGASUS) tha …
This review summarizes findings from three studies in complement-inhibitor-naive patients with PNH (PADDOCK [phase Ib], PALOMINO [phase IIa] …
PEGASUS: the Design of an Intervention to Facilitate Shared Decision-making in Breast Reconstruction.
Clarke A, Paraskeva N, White P, Tollow P, Hansen E, Harcourt D. Clarke A, et al. J Cancer Educ. 2021 Jun;36(3):508-518. doi: 10.1007/s13187-019-01656-6. J Cancer Educ. 2021. PMID: 31994007 Free PMC article. Clinical Trial.
PEGASUS is a standardised two-stage process, in which patients' goals are first elicited, ranked in importance and recorded before being used to frame discussion and decision-making with the surgeon managing care. ...This is intended to facilitate replication by other clin …
PEGASUS is a standardised two-stage process, in which patients' goals are first elicited, ranked in importance and recorded before be …
956 results